Global Patient & Market Access

 

Global Market and Patient Access, Wednesday 29 April 2020

last published: 17/Jan/20 21:45

 

Global Market and Patient Access, Thursday 30 April 2020

Emil Kakkis
08:30

Keynote Address: The future of rare diseases: developing and accessing the next generation of therapies

Mark Rothera
08:55

Sponsored Keynote Address: Gene therapy: the future is now

10:30

10:30 SPEED NETWORKING FOLLOWED BY MORNING NETWORKING BREAK

Emerging Markets

Rania Ashraf
Global Market and Patient Access
11:30

MENA: Working with multiple stakeholders in the region to enable access to treatment for rare diseases patients

Global Market and Patient Access
11:50

GOLD SPONSOR SESSION

If you are interested in sponsoring this session, contact André Singer now at +1 646 619 1797 or andre.singer@terrapinn.com
Jan Nielsen
14:20

ROUNDTABLE 10: Patient and provider experiences - A tailored tech + talent approach to enhance the journey

Rachel Sher
14:20

ROUNDTABLE 11: Orphan Drug Act-assessing the impact since 1983 and looking forward

Alexander Natz
14:20

ROUNDTABLE 12: Real World Evidence – examining recent cases of real world evidence for approvals and reimbursement in Europe

Sara Nochur
14:20

ROUNDTABLE 16: Diversity & inclusion - The importance of D&I in a global company - exploring its impact on employee morale, engagement and retention of workforce, and also the need for D&I in clinical

Jennifer Helfer
14:20

ROUNDTABLE 17: Internal Patient Perspective – blocking and tackling actionable implementation of patient voice throughout company functions

Debbie Drell
14:20

ROUNDTABLE 18: Splinter Groups - How to advance your organization, unify communities and focus on your mission while navigating challenges with personalities, emotions and leadership differences among

Scott Schliebner
14:20

ROUNDTABLE 1: Reducing study burden – approaches for assessing and reducing the burden of clinical trial participation for patients

14:20

ROUNDTABLE 23: Gene therapy education – best practices for educate patient populations on the science and implications of gene therapy

Chelsea Catsburg
14:20

ROUNDTABLE 2: Synthetic control arms - using RWE to streamline the regulatory process

Scott Gray
14:20

ROUNDTABLE 3: The patient journey - improving clinical trial performance and delivering better study outcomes through a personalized approach to the patient experience

Anne Cropp
14:20

ROUNDTABLE 4: Early Access – effective measures for successful EAPs

Meagan Spychala
14:20

ROUNDTABLE 5: Patient-Focused Drug Development – how to get started

Amanda Finlayson
14:20

ROUNDTABLE 6: Balancing the Patient Experience & ROI – understanding when to incorporate patient accommodations into study programs and balancing short and long term financial goals

Michelle Berg
14:20

ROUNDTABLE 7: Gene therapy CMC – early pDNA considerations for late stage success

David Lapidus
14:20

ROUNDTABLE 8: Forecasting & epidemiology - rare-disease epidemiology methods and resources to support commercial forecasts

Becky Thompson
14:20

ROUNDTABLE 9: Access Programs - discussion on the value of rare and orphan access programs, next generation registries and post marketing surveillance for products

ROUNDTABLE SESSIONS (1-hour roundtable sessions split between 2 rounds of 30min) – Sign up for two roundtables by registration

3:20 END OF ROUNDTABLES

Evolving Regulation

Bernard Grimm
Global Market and Patient Access
15:25

EUROPE: Update on the current review of orphan drug incentives in Europe – what could change and how would these changes impact drug developers, patient access and overall business models

Global Market and Patient Access
15:45

COLOMBIA: Market access challenges and updated orphan drug regulation

Speaker to be announced
Global Market and Patient Access
16:05

INDIA: Update on advanced therapies regulation and clinical development opportunities for rare diseases

Speaker to be announced
Global Market and Patient Access
16:25

GOLD SPONSOR SESSION

If you are interested in sponsoring this session, contact André Singer now at +1 646 619 1797 orandre.singer@terrapinn.com
16:45

4:45 AFTERNOON NETWORKING BREAK

Nick Page
17:25

Keynote Address: KYMRIAH case study: what it takes to bring an organization from clinical to commercial scale for vector manufacture

18:05

END OF CONFERENCE DAY 1 FOLLOWED BY NETWORKING DRINKS RECEPTION

last published: 17/Jan/20 21:45